Literature DB >> 28819284

Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Y Zhou1, B L Wood1, R B Walter2,3, P S Becker2,3, M-E Percival2,3, M Bar3,4, C Shaw3, K Gardner2, P Hendrie2, J Abkowitz2, F R Appelbaum3,4, E Estey2,3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28819284     DOI： 10.1038/leu.2017.263

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  9-color and 10-color flow cytometry in the clinical laboratory.

Authors:  Brent Wood
Journal:  Arch Pathol Lab Med       Date:  2006-05       Impact factor: 5.534

2.  Flow cytometric monitoring of residual disease in acute leukemia.

Authors:  Brent L Wood
Journal:  Methods Mol Biol       Date:  2013

3.  NCCN Clinical Practice Guidelines Acute myeloid leukemia.

Authors:  Margaret R O'Donnell; Camille N Abboud; Jessica Altman; Frederick R Appelbaum; Daniel A Arber; Eyal Attar; Uma Borate; Steven E Coutre; Lloyd E Damon; Salil Goorha; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Martin S Tallman; Eunice S Wang; Maoko Naganuma; Kristina M Gregory
Journal:  J Natl Compr Canc Netw       Date:  2012-08       Impact factor: 11.908

4.  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Authors:  Hiroto Inaba; Elaine Coustan-Smith; Xueyuan Cao; Stanley B Pounds; Sheila A Shurtleff; Kathleen Y Wang; Susana C Raimondi; Mihaela Onciu; Jeffrey Jacobsen; Raul C Ribeiro; Gary V Dahl; W Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

5.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Authors:  Monique Terwijn; Wim L J van Putten; Angèle Kelder; Vincent H J van der Velden; Rik A Brooimans; Thomas Pabst; Johan Maertens; Nancy Boeckx; Georgine E de Greef; Peter J M Valk; Frank W M B Preijers; Peter C Huijgens; Angelika M Dräger; Urs Schanz; Mojca Jongen-Lavrecic; Bart J Biemond; Jakob R Passweg; Michel van Gelder; Pierre Wijermans; Carlos Graux; Mario Bargetzi; Marie-Cecile Legdeur; Jurgen Kuball; Okke de Weerdt; Yves Chalandon; Urs Hess; Leo F Verdonck; Jan W Gratama; Yvonne J M Oussoren; Willemijn J Scholten; Jennita Slomp; Alexander N Snel; Marie-Christiane Vekemans; Bob Löwenberg; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

8.  Routine bone marrow exam during first remission of acute myeloid leukemia.

Authors:  E Estey; S Pierce
Journal:  Blood       Date:  1996-05-01       Impact factor: 22.113

Review 9.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Authors:  David Grimwade; Sylvie D Freeman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

Review 10.  Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Authors:  Sarah A Buckley; Brent L Wood; Megan Othus; Christopher S Hourigan; Celalettin Ustun; Michael A Linden; Todd E DeFor; Michele Malagola; Chloe Anthias; Veronika Valkova; Christopher G Kanakry; Bernd Gruhn; Francesco Buccisano; Beth Devine; Roland B Walter
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941
View more
  4 in total

1.  The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia.

Authors:  B Said; S Gilles; D Weisdorf; A Rashidi
Journal:  Leukemia       Date:  2017-10-31       Impact factor: 11.528

2.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects.

Authors:  Jan-Niklas Eckardt; Martin Bornhäuser; Karsten Wendt; Jan Moritz Middeke
Journal:  Blood Adv       Date:  2020-12-08

4.  Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Authors:  Mary-Elizabeth Percival; Hai-Lin Wang; Mei-Jie Zhang; Wael Saber; Marcos de Lima; Mark Litzow; Partow Kebriaei; Hisham Abdel-Azim; Kehinde Adekola; Mahmoud Aljurf; Ulrike Bacher; Sherif M Badawy; Amer Beitinjaneh; Nelli Bejanyan; Vijaya Bhatt; Michael Byrne; Jean-Yves Cahn; Paul Castillo; Nelson Chao; Saurabh Chhabra; Edward Copelan; Corey Cutler; Zachariah DeFilipp; Ajoy Dias; Miguel Angel Diaz; Elihu Estey; Nosha Farhadfar; Haydar A Frangoul; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Lohith Gowda; Michael Grunwald; Nasheed Hossain; Rammurti T Kamble; Christopher G Kanakry; Ankit Kansagra; Mohamed A Kharfan-Dabaja; Maxwell Krem; Hillard M Lazarus; Jong Wook Lee; Jane L Liesveld; Richard Lin; Hongtao Liu; Joseph McGuirk; Reinhold Munker; Hemant S Murthy; Sunita Nathan; Taiga Nishihori; Richard F Olsson; Neil Palmisiano; Jakob R Passweg; Tim Prestidge; Olov Ringdén; David A Rizzieri; Witold B Rybka; Mary Lynn Savoie; Kirk R Schultz; Sachiko Seo; Akshay Sharma; Melhem Solh; Roger Strair; Marjolein van der Poel; Leo F Verdonck; Jean A Yared; Daniel Weisdorf; Brenda M Sandmaier
Journal:  Bone Marrow Transplant       Date:  2021-04-16       Impact factor: 5.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.